Pacritinib Citrate

枸橼酸帕克替尼

Report date: 2026/05/05 20:00:16
NME

Base Information

Drug NamePacritinib Citrate
Drug Alias Namepacritinibum帕瑞替尼Pacritinib帕利替尼帕克替尼 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsJAK2 V617F inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[6] 
TargetsTyrosine-protein kinase JAK2JAK2 V617FTyrosine-protein kinase receptor FLT3 +[6] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)VEXAS SyndomeGraft vs Host Disease +[33] 
Global Approved IndicationsPrimary Myelofibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/02/28
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesS*BIO Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSobiSwedish Orphan Biovitrum (Sobi)Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas +[13] 
Inactive CompaniesWeill Medical College of Cornell UniversityBaxalta IncorporatedThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsVEXAS SyndomeGraft vs Host DiseaseCastleman Disease +[20] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Carcinoma, Non-Small-Cell LungColorectal Neoplasms +[13] 

Other Information

ATC CodeN/A
Related LinksN/A